Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278072 | 0.79 | ROCK2 (0.40) | KCNH2GRM2TNIKARTSHR | |
| SCHEMBL11985664 | 0.79 | PRMT5 (0.49) | TNIKARTSHRROCK2ROCK1 | |
| SCHEMBL3277729 | 0.79 | KCNH2 (0.46) | KCNH2GRM2TNIKROCK2ROCK1 | |
| SCHEMBL13277913 | 0.78 | TNIK (0.43) | KCNH2GRM2TNIKARTSHR | |
| SCHEMBL16488375 | 0.77 | DDB1 (0.47) | KCNH2ARTSHRMAPK1 | |
| SCHEMBL14552616 | 0.76 | MAPK1 (0.47) | TNIKARROCK2ROCK1MAPK1 | |
| SCHEMBL3275684 | 0.76 | KCNH2 (0.39) | KCNH2GRM2ARMAPK1PREP | |
| SCHEMBL3277116 | 0.75 | PRMT5 (0.54) | TNIKARROCK2ROCK1MAPK1 | |
| SCHEMBL3277147 | 0.75 | ROCK2 (0.49) | KCNH2TNIKARTSHRROCK2 | |
| SCHEMBL14552587 | 0.74 | MAPK1 (0.43) | KCNH2GRM2TNIKARROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | KCNH2 1467/4885GRM2 247/4885TNIK 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.